

Ulrich P. Steiner, Ph.D.

Dr. Steiner joined the Pharmaceutical Division of Bayer in Germany in 1984 and developed key components of Bayer's mammalian cell culture fermentation technologies, as e.g. implemented in the large scale, high density, continuous fermentation process for rFVIII (Kogenate®). After transferring to Bayer's Biotechnology unit in Berkeley, California in 1994 and initially running a GMP fermentation pilot plant for antibody production, he focused largely on cost issues and concepts for designing and running large scale mammalian facilities from a strategic perspective. The evaluation of alternative technologies, like, e.g., transgenic production technologies, became an obvious consequence of addressing those questions.

Before joining Bayer, he was staff scientist at the University of Konstanz, Germany. He did his post-doc at the University of Colorado in Boulder, CO, after receiving his Ph.D. degree in Biophysics at the University of Konstanz, Germany in 1980. Dr. Steiner graduated in Nuclear Physics at the University of Marburg, Germany in 1975.